Trials / Unknown
UnknownNCT00930501
Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients
Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- Female
- Age
- 5 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.
Detailed description
our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | blood tests | time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-12-01
- Completion
- 2013-12-01
- First posted
- 2009-06-30
- Last updated
- 2009-06-30
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00930501. Inclusion in this directory is not an endorsement.